Literature DB >> 27227698

Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma.

William C McDonald, Nilanjana Banerji, Kelsey N McDonald, Bridget Ho, Virgilia Macias, Andre Kajdacsy-Balla1.   

Abstract

CONTEXT: -Pituitary adenoma classification is complex, and diagnostic strategies vary greatly from laboratory to laboratory. No optimal diagnostic algorithm has been defined.
OBJECTIVE: -To develop a panel of immunohistochemical (IHC) stains that provides the optimal combination of cost, accuracy, and ease of use.
DESIGN: -We examined 136 pituitary adenomas with stains of steroidogenic factor 1 (SF-1), Pit-1, anterior pituitary hormones, cytokeratin CAM5.2, and α subunit of human chorionic gonadotropin. Immunohistochemical staining was scored using the Allred system. Adenomas were assigned to a gold standard class based on IHC results and available clinical and serologic information. Correlation and cluster analyses were used to develop an algorithm for parsimoniously classifying adenomas.
RESULTS: -The algorithm entailed a 1- or 2-step process: (1) a screening step consisting of IHC stains for SF-1, Pit-1, and adrenocorticotropic hormone; and (2) when screening IHC pattern and clinical history were not clearly gonadotrophic (SF-1 positive only), corticotrophic (adrenocorticotropic hormone positive only), or IHC null cell (negative-screening IHC), we subsequently used IHC for prolactin, growth hormone, thyroid-stimulating hormone, and cytokeratin CAM5.2.
CONCLUSIONS: -Comparison between diagnoses generated by our algorithm and the gold standard diagnoses showed excellent agreement. When compared with a commonly used panel using 6 IHC for anterior pituitary hormones plus IHC for a low-molecular-weight cytokeratin in certain tumors, our algorithm uses approximately one-third fewer IHC stains and detects gonadotroph adenomas with greater sensitivity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27227698     DOI: 10.5858/arpa.2016-0082-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  7 in total

Review 1.  A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.

Authors:  C Villa; A Vasiljevic; M L Jaffrain-Rea; O Ansorge; S Asioli; V Barresi; L Chinezu; M P Gardiman; A Lania; A M Lapshina; L Poliani; L Reiniger; A Righi; W Saeger; J Soukup; M Theodoropoulou; S Uccella; J Trouillas; F Roncaroli
Journal:  Virchows Arch       Date:  2019-10-02       Impact factor: 4.064

2.  Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers.

Authors:  Joao Paulo Almeida; Corbin C Stephens; Jennifer M Eschbacher; Michelle M Felicella; Kevin C J Yuen; William L White; Michael A Mooney; Anne Laure Bernat; Ozgur Mete; Gelareh Zadeh; Fred Gentili; Andrew S Little
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 3.  Overview of the 2022 WHO Classification of Pituitary Tumors.

Authors:  Sylvia L Asa; Ozgur Mete; Arie Perry; Robert Y Osamura
Journal:  Endocr Pathol       Date:  2022-03-15       Impact factor: 3.943

4.  Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.

Authors:  Julieann C Lee; Melike Pekmezci; Jonathan L Lavezo; Hannes Vogel; Laurence Katznelson; Merav Fraenkel; Griffith Harsh; Mohanpal Dulai; Arie Perry; Tarik Tihan
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

Review 5.  Histopathological classification of non-functioning pituitary neuroendocrine tumors.

Authors:  Emilija Manojlovic-Gacic; Britt Edén Engström; Olivera Casar-Borota
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

6.  Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.

Authors:  Yiyuan Chen; Hua Gao; Qian Liu; Weiyan Xie; Bin Li; Sen Cheng; Jing Guo; Qiuyue Fang; Haibo Zhu; Zhuang Wang; Jichao Wang; Chuzhong Li; Yazhuo Zhang
Journal:  Aging (Albany NY)       Date:  2020-12-29       Impact factor: 5.682

7.  Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway.

Authors:  Richard A Hickman; Jeffrey N Bruce; Marc Otten; Alexander G Khandji; Xena E Flowers; Markus Siegelin; Beatriz Lopes; Phyllis L Faust; Pamela U Freda
Journal:  Neuropathol Appl Neurobiol       Date:  2020-12-20       Impact factor: 8.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.